|
23andMe, co-founded by Anne Wojcicki, the wife of Google
co-founder Sergey Brin, will contribute the genome sequencing
and data from its Parkinson's disease community. Genentech, a
unit of Roche Holding AG, will work to identify potential
therapeutics based on that information.
There is no cure for Parkinson's, which affects about 1 million
people in the United States, but some medications can improve
symptoms.
Under the agreement between the two companies, after the
multi-year deal ends, 23andMe can conduct additional research on
the data and make it available to other Parkinson's researchers.
The data will be de-identified and contributed only by
individuals who provide explicit permission to 23andMe, the
company said.
(Reporting by Caroline Humer; Editing by Leslie Adler)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
|
|
